| |
China's Hepatitis C Prevalent Population is Ten Times that of the United States
|
| |
| |
Price Cuts by the Government or Drug Manufacturers Could Expand the HCV Market
New Report Series from Decision Resources Offers the Most Comprehensive Analysis of Pharmaceutical Markets in China
WALTHAM, Mass., Dec. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, estimates that China's hepatitis C virus (HCV) prevalent population is ten times that of the United States. This large prevalent population, combined with the country's rapid economic growth, makes it an important region of expansion for companies with HCV products.
"Nearly 45 million people in China have chronic HCV, a population ten times the size of that in the United States," said Aaron Woolsey, Ph.D., analyst at Decision Resources. "Although diagnosis rates and drug-treatment rates are currently quite low, small increases in these rates will have a significant impact on the overall market, and substantial increases in diagnosis or drug-treatment of this underdiagnosed and undertreated population would result in phenomenal expansion of this relatively sleepy market."
The new Hepatitis C in China report also finds that China's therapeutic
markets for HCV will remain a heavily cash-based economy and that new
insurance schemes will not adequately cover therapies that cost more than
five times the annual per capita income. Paradoxically, price cuts -
implemented by the government or drug manufacturers - could expand the HCV
market.
"Price cuts to the more expensive regimens could help position these
drugs in a more affordable price range for a large percentage of urban
patients who are currently forced to accept a less-effective, cheaper
therapeutic because the high cost of the best treatment regimens are beyond
their means," continued Dr. Woolsey.
This new report from Decision Resources assesses the commercial
opportunity in the Chinese pharmaceutical market for hepatitis C treatments
based on population dynamics, economic development, disease epidemiology,
and changing physicians' practices. Key elements of each report in our
Emerging Markets - China series include the following:
-- Accurate sizing of the patient population with access to Western
medicine.
-- Projections for future patient populations based on trends in
lifecycle, urbanization, and economic status.
-- Current treatment patterns and drivers of choice.
-- Physician-defined unmet needs in diagnosing and treating the disease.
-- Disease-specific pricing and reimbursement environment.
-- Key drivers of market growth.
About Emerging Markets - China
Emerging Markets - China is the first and only syndicated report series
focusing on high-growth emerging markets with comprehensive
disease-specific analysis. With these reports, biopharmaceutical companies
can accomplish the following:
-- More accurately assess their commercial opportunity for Western brands
in China.
-- Understand the physician treatment patterns and drivers of choice in
key urban areas based on primary research.
-- Gain a clear perspective from a five-year, drug-level market forecast,
which is broken out by multinational sales versus Chinese-based
companies.
About Decision Resources
Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader
in healthcare market research publications, advisory services, and
consulting designed to help clients shape strategy, allocate resources, and
master their chosen markets.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
|
|
| |
| |
|
|
|
